Ann: OrthoATI Tendon Clinical Study Success, page-232

What was that Football, you don't understand ASES or VAS scores?

Well, whilst ASES scores for shoulder are a pain and function composite score measured from 0-100, yes, the reality is the normal population is never 100 and even in young healthy adults WITHOUT shoulder symptoms is less than 99:

https://www.jshoulderelbow.org/article/S1058-2746(08)00630-7/fulltext

Yes Football, ASES scores are usually much lower with age and tendon degeneration, so that OCC's OrthoATI achieved 93.3 ASES scores at 12 months in patients suffering from pain and loss of shoulder function for almost 2 years, having received an average of 4 failed treatments, prior to enrolment, is quite remarkeable.

VAS scores are from 0-10 and a simple pain score. Yes, Football, that ATI patients pain reduced from 4.8 pre-treatment to 1.6 at 12 months post treatment is pretty remarkeable, especially against the corticosteroid participant group only seeing the average VAS pain score reduced 0.9 points from 5.2 pre-treatment to 4.3 at 12 months posttreatment. Its resoundingly the case, that corticosteroids only provide temporary pain relief and disappointing that they are still the 'go to' standard of care.

Yes Football, it is going to be interesting to see how patients, who underwent corticosteroids in the trials, that then eventually had ATI, compare to their low ASES scores pre and post corticosteroids. Yes it will be pretty convincing if ATI saw scores of 93.3 vs the corticosteroid control group that started at 62.6 and finished at 62.9 are then consolidated by that same control cohort pushed up to 90+ to on being granted ATI post the first trial (kind of two trials from one).

Yes Football, the results do give indication into OCC's other rendomised controlled trial in OrthoATI vis surgery, where, unfortunately for patients, ASES scores as low as 76 and a VAS score of 1.6 are deemed acceptable outcomes in shoulder arthroplasty :

https://journals.sagepub.com/doi/pdf/10.1177/2471549217720042#:~:text=Conclusions%3A%20Patients%20treated%20with%20a,to%20reach%20an%20acceptable%20state.

Yes I agree Football. It could all be very compelling data for Johnson and Johnson to join OCC in a partnership in ATI, before another suitor like BioHorizons in their Sriate product jumps in.

Thanks for your interest in OCC threads. The share price still essentially suffers from the company's anonymity despite delivering patients with unmet needs like Quadraplegics real quality of life changes, so be a darling and spread the good word on their trial and regulatory success, that they've finally added to with commercial success.